In response to dosing omalizumab in allergic asthma

The efficacy and safety of omalizumab were demonstrated prospectively in phase III clinical trials,2-4 which subsequently led to Food and Drug Administration approval of omalizumab and inclusion of the accompanying dosing table in the US product label.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of allergy and clinical immunology 2007, Vol.119 (1), p.255-256
Hauptverfasser:	Jaffe, Jonathan S., MD, Massanari, Marc, PharmD
Format:	Artikel
Sprache:	eng
Schlagworte:	Allergy and Immunology Anti-Asthmatic Agents - administration & dosage Antibodies, Anti-Idiotypic Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Asthma - drug therapy Clinical trials Humans Immunoglobulin E - blood Omalizumab Pharmaceutical industry
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The efficacy and safety of omalizumab were demonstrated prospectively in phase III clinical trials,2-4 which subsequently led to Food and Drug Administration approval of omalizumab and inclusion of the accompanying dosing table in the US product label.
ISSN:	0091-6749 1097-6825
DOI:	10.1016/j.jaci.2006.10.026